ArticleJournal of diabetes research2026
Risk Stratification for Diabetic Kidney Disease Progression in Predicting All-Cause and Cardiovascular Mortality in Type 2 Diabetes: A National Cohort Study From NHANES 1999-2018.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) substantially contributes to premature mortality in individuals with Type 2 diabetes (T2D). Although the 2024 American Diabetes Association (ADA) guideline incorporates the risk stratification of DKD progression into routine diabetes care, its predictive validity for mortality remains underexplored in real-world populations. Using data from 6936 adults with T2D enrolled in the US National Health and Nutrition Examination Survey (NHANES) from 1999 to 2018, this study examined whether baseline DKD progression risk categories-based on estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR)-can predict all-cause and cardiovascular mortality. Risk of DKD progression was classified as low, moderately increased, high, or very high. Mortality outcomes were identified via linkage to the National Death Index until December 31, 2019. Cox proportional hazards models were used to estimate hazard ratios (HRs), adjusting for demographics, comorbidities, lifestyle behaviors, laboratory values, and medication use. Over a median follow-up of 98 months, 1781 all-cause and 623 cardiovascular deaths occurred. Compared with the low-risk group, the very high-risk group had significantly higher risks of all-cause mortality (adjusted HR: 2.53; 95% CI: 2.15-2.98) and cardiovascular mortality (adjusted HR: 2.47; 95% CI: 1.87-3.27), with a clear dose-response gradient across risk categories (p for trend < 0.001). Notably, this graded relationship remained stable across most examined subgroups, and significant interactions were observed specifically among individuals aged < 65 years and those using renin-angiotensin system (RAS) inhibitors. These findings confirm the robust prognostic utility of the ADA-endorsed risk stratification matrix of DKD progression for mortality in T2D and highlight its potential to inform risk-based individualized management strategies in clinical practice. This study also provides pragmatic evidence supporting the implementation of guideline recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.